Clinical trials: AIDS Vaccines
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV, Cancer
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV.
- Trial name
- NCT01205581
- Testing
- Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- St. Jude Children's Research Hospital
Tuberculosis
Study of AERAS-402 in Healthy Infants
AERAS-402 will be given to infants of at least 16 weeks of age who have already been vaccinated with BCG to determine if AERAS-402 will increase protection of infants to tuberculosis.
- Trial name
- NCT01198366
- Testing
- AERAS-402 1.5 x 10^10 vp, AERAS-402 3.0 x 10^10 vp, AERAS-402 1.0 x 10^11 vp
- Where
- 7 sites in Kenya, Mozambique and 1 more
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Aeras
Infections, Streptococcal
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
The purposes of this study: To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a…
- Trial name
- NCT00829010
- Testing
- Pneumococcal vaccine GSK1024850A, Tritanrix-HepB/Hib, measles
- Where
- South Africa
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diarrhoea
Causes of Rotavirus Vaccine Failure in Zambian Children
Zambia recently introduced routine infant immunization against rotavirus - the most important cause of severe gastroenteritis and diarrhoea mortality in children.
- Trial name
- NCT01886833
- Where
- Zambia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Pneumococcal Infections
Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
This is a study of V114 in children infected with HIV. Participants will be randomly assigned in a 1:1 ratio to receive either V114 or Prevnar 13™ followed 8 weeks later by a single dose of PNEUMOVAX™23.
- Trial name
- PNEU-WAY PED (NCT03921424)
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 13 sites in South Africa, Thailand and 1 more
- Volunteers
- 407 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Meningitis
Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth
Bacterial meningitis infection is common in youth 2 to 24 years of age in the United States. This disease can be treated by antibiotics, but mortality rates associated with meningitis of up to 53% have been estimated.
- Trial name
- NCT00459316
- Testing
- Quadrivalent meningococcal conjugate vaccine
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 384 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
- Trial name
- HVTN 135 (NCT04607408)
- Testing
- CH505TF gp120, GLA-SE adjuvant
- Where
- South Africa
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infections, Pneumococcal Infections
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a…
- Trial name
- NCT00962780
- Testing
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS), Blood draw
- Where
- 11 sites in Romania, South Africa
- Volunteers
- 303 people
- Sponsor
- Pfizer
Hepatitis B
Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate immunogenicity of the products in this population, barriers…
- Trial name
- NCT00107042
- Testing
- Recombivax, Twinrix
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HPV Infection, Hiv
HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini
This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini.
- Conditions
- HPV Infection, Hiv, HPV Vaccine
- Trial name
- NCT04982614
- Testing
- Gardasil ® 9
- Where
- 5 sites in Eswatini
- Volunteers
- 1,403 people
- Sponsor
- Columbia University
Human Immunodeficiency Virus (HIV)
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are…
- Trial name
- QLAIV (NCT02474901)
- Testing
- Quadrivalent Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo.
- Trial name
- NCT02564523
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Anal Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection.
- Conditions
- Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
- Trial name
- NCT01209325
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
- Where
- 19 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infection
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
The purpose of this study is to evaluate the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in HIV-infected young women.
- Trial name
- NCT00710593
- Testing
- HPV vaccine for strains -6, -11, -16, and -18
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 99 people
- Sponsor
- University of North Carolina, Chapel Hill
Respiratory Syncytial Virus
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
The purpose of the study is to learn about the safety and immune activity of the RSVpreF vaccine. It will be studied in infants born to mothers living with HIV.
- Trial name
- MORISOT (NCT06325657)
- Testing
- RSVpreF vaccine, Placebp
- Where
- 14 sites in South Africa
- Volunteers
- 681 people
- Sponsor
- Pfizer
HIV Infection, Hepatitis B
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
Hepatitis B is a contagious virus that can damage a person's liver. It can be prevented by vaccination, but for many HIV-positive people, the vaccines do not help them achieve adequate protection against this virus.
- Trial name
- NCT00106964
- Testing
- Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
- Where
- 11 sites in United States, Brazil and 1 more
- Volunteers
- 371 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infection, Rotavirus Infection
Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
Rotavirus is the leading cause of severe diarrhea in infants and young children, accounting for 45% of severe diarrhea disease in both developed and developing countries.
- Trial name
- NCT00880698
- Testing
- RotaTeq
- Where
- 6 sites in Botswana, Tanzania and 2 more
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sexual Transmission of Infection
Preparedness Study - HPV Vaccine
Moffitt Cancer Center is the Coordinating Center for this study. The purpose of this study is to develop and test the infrastructure to conduct a future Phase III vaccine efficacy trial to assess trial feasibility, and to assess…
- Trial name
- NCT01489527
- Testing
- Gardasil Vaccine
- Where
- 2 sites in United States, South Africa
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Infections, Rotavirus
A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa
The aim of this study is to evaluate the reactogenicity, safety and immunogenicity of GSK Biologicals' human rotavirus (HRV) vaccine given concomitantly with routine vaccines including OPV in HIV positive infants.
- Trial name
- NCT00263666
- Testing
- Rotarix, Tritanrix-HB+Hib, Polio Sabin
- Where
- 6 sites in South Africa
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline